Does nicotine offer neuroprotection?

What the evidence says

Nicotine is the chemical in tobacco and vaping products that affects the brain and causes addiction. Scientists have long noticed that people who smoke seem to get Parkinson's disease less often than non-smokers, and this sparked interest in whether nicotine itself protects brain cells.

In lab dishes and animal studies, nicotine does seem to shield dopamine-producing brain cells, the type that die off in Parkinson's disease. It appears to work by attaching to a specific docking point on brain cells called the α7 nicotinic receptor, which then reduces inflammation and cell damage. Similar protective effects have been seen against the sticky brain protein linked to Alzheimer's disease.

However, these promising lab findings have not held up well in real people. A 2024 analysis pooling multiple human trials found that giving people nicotine did not meaningfully improve their movement symptoms or thinking skills in Parkinson's disease. Likewise, a thorough review of the evidence found no proof that nicotine helps people with Alzheimer's disease, even though small studies suggested short-term attention improvements.

One likely reason for this mismatch is timing. By the time Parkinson's or Alzheimer's is diagnosed, a lot of brain cell loss has already happened, so protecting cells at that late stage may be too little, too late, even if nicotine could help earlier on.

It's also worth knowing that nicotine is not risk-free. Health authorities in Canada and elsewhere warn that nicotine itself, in any form including vaping, harms the heart and blood vessels and raises the risk of high blood pressure and heart disease. Any potential brain benefit needs to be weighed against these known harms.